HOME >> MEDICINE >> NEWS
Media focus on endostatin helped -- not hurt --

that heralded the discovery and development of an agent called recombinant human endostatin (rh-Endo), an angiogenesis inhibitor designed to dry up a tumor's source of blood, starving it. In the article, researchers predicted endostatin might quickly prove to be a cure for cancer. The media blitz that followed was unusual in medical reporting because the drug had not been formally tested in humans.

When M. D. Anderson researchers geared up to run a small Phase I clinical trial of rh-Endo -- one of three centers in the country to conduct such a study -- they were ethically concerned that such "hyperbolic" coverage both in 1998 and at the launch of the clinical trials might draw patients who had little understanding of the purpose of a Phase I clinical trial, but were solely focused on the drug's ability to save their lives. Patients admitted into this beginning phase of testing have no curative treatment options, yet these trials are designed to determine safety and optimal dose, and monitor effectiveness -- it is not intended to prove clinical benefit.

To see if their worries were justified, they asked patients who were referred to the trial from physicians at M. D. Anderson to participate in a survey. Some of these patients were not being cared for at M. D. Anderson, but subsequently contacted the cancer center in the hopes of being seen and referred to the trial.

The seven-member ethics research team analyzed media coverage of the agent from 1997 to 2000 in three newspapers known for medical reporting -- The New York Times, Boston Globe and Chicago Tribune. They found that the majority of coverage was generally positive on the promise of endostatin -- only 25 percent of the articles gave what researchers called a "factual account."

They then surveyed 100 patients referred to the endostatin trial between October 1999 and November 2000. Almost half of survey participants (47 percent) had heard about endostatin from media sources, and 51 pe
'"/>

Contact: Julie Penne or Laura Sussman
jpenne@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
13-Sep-2002


Page: 1 2 3 4

Related medicine news :

1. Media update: GSA underscores hottest meeting topics
2. Media invitation first annual EDCTP Forum
3. Media invitation - European Society of Cardiology Congress 2004
4. Media invitation: The Movement Disorder Societys 7th International Congress
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Review of preliminary observations concludes the Mayo Clinic Natl Conf on Medicine and the Media
7. Media undermine efforts to tackle nicotine addiction
8. Media advisory: Mayo Clinic study finds infliximab safe and beneficial for Crohns disease
9. Media coverage of new drugs is often misleading
10. Media advisory: Mayo Clinic study shows increased incidence of migraines in women
11. American Heart Association Media Advisory: Cholesterol Lowering Margarines

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Media focus endostatin helped not hurt

(Date:7/28/2014)... 28, 2014 Quincy Bioscience, makers of ... pleased to announce the release of the fourth edition ... and co-founder Mark Underwood. , The Brain Health Guide ... useful techniques for readers to improve memory and promote ... conclusion, The Brain Health Guide provides ways to help ...
(Date:7/28/2014)... 2014 (HealthDay News) -- Elementary school students seem to be ... according to a new study of school officials. , , ... Agriculture -- went into effect in the fall of 2012. ... buying lunch, or throw away most of their food. But ... this isn,t the case. , , "The updated meals standards ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Shofner ... Operation Military June . Renowned LASIK and Cataract ... to provide significant funds and public awareness for ... retired military personnel and their families. “This was ... proudly give nearly $5,000 to a variety of ...
(Date:7/28/2014)... By Maureen Salamon ... (HealthDay News) -- Infants and children who are at ... should be vaccinated against the infection, according to updated ... States. And routine vaccinations for the potentially ... the American Academy of Pediatrics says. In its ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, 2014 ... irregularities are more likely to get a pacemaker than people ... study of more than 16,000 people found that those with ... a pacemaker than those without the memory-robbing condition. ... dementia are so much more likely to be treated with ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Healthy School Lunches Get Thumbs Up From Students 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3
(Date:7/28/2014)... 28, 2014  VigeneTech, Inc, in collaboration with ... Data Analysis Software, an OEM software solution for ... develops and offers varieties of bead-based multi-analyte immunoassay ... support of VigeneTech,s data analysis software, FCS data ... easily reported LEGENDplex™ software is ...
(Date:7/28/2014)... , July 28, 2014 Research and Markets ... Drugs Market 2014-2018" report to their offering. ... chronic disease that leads to inflammation and pain in the ... ankles. In addition, it causes inflammation of the tissues that ... The symptoms of RA begin slowly, usually just mild ...
(Date:7/28/2014)... 28, 2014  Syneron Medical Ltd. (NASDAQ: ... today that its new PicoWay® device has received CE ... colors and pigmented lesions on any skin type. PicoWay ... 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary PicoWay ... which are trillionths of a second, known as picosecond ...
Breaking Medicine Technology:VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4
Cached News: